ClinicalTrials.gg
RecruitingNCT06521541Updated Jul 26, 2024

Whole Course Multi-model Prehabilitation to Improve Clinical Outcome in Patients Undergoing Neoadjuvant Treatment Prior to Gastrectomy

An interventional study of Multimodal prehabilitation program and ERAS program in Gastric Cancer and Prehabilitation, sponsored by The Affiliated Hospital of Qingdao University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-26.

Sponsored by The Affiliated Hospital of Qingdao University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Stomach Neoplasms by The Affiliated Hospital of Qingdao University — 12 open to participants now, 14 under way, 1 of them phase 3. Stomach Neoplasms · The Affiliated Hospital of Qingdao University.

Planned enrollment
10th of 13
90 · median 300
Started
2024
with 2 others
No phase
12 of 16
9 open now
Primary completion
2025-01
later than 5 of 13 live
Registered
9th of 16
by date

Among the 16 studies in Stomach Neoplasms by The Affiliated Hospital of Qingdao University, this one is the 10th largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2024, is one of 12 with no phase, reaches primary completion later than 5 of the 13 other live ones, and was the 9th registered.

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

12 of the 16 studies in Stomach Neoplasms by The Affiliated Hospital of Qingdao University are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Stomach Neoplasms by The Affiliated Hospital of Qingdao University, or all of them as a file.
02

Study summary

The intention of research is to establish a multimodal prehabilitation protocol in patients who undergo neoadjuvant chemotherapy prior to gastrectomy, explore the feasibility and effectiveness of the measures and evaluate the effect of program on short-term clinical outcome, fitness and long-term prognosis.

03

Conditions studied

  • Gastric Cancer
  • Prehabilitation

Browse trials for

Keywords

  • Multimodal prehabilitation
  • Neoadjuvant chemotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged ≥18 years;
  2. (ECOG) performance status score ≤2;
  3. Endoscopic were confirmed as gastric adenocarcinoma;
  4. The feasibility of therapy was suggested by MDT, and the feasibility of radical gastrectomy was re-evaluated after neoadjuvant therapy;
  5. Blood routine, liver function, kidney function, heart function and lung function were normal before neoadjuvant therapy, and there was no of chemotherapy and surgery;
  6. The pregnancy test was negative within 1 month, and she was not pregnant or breastfeeding;
  7. and ability to comply with research protocols.

Exclusion criteria

Exclusion Criteria:

  1. ;
  2. End-stage cardiac insufficiency (\<30% or class IV), liver cirrhosis ( classification C), End-stage renal failure (receives chronic dialysis), or IV;
  3. Cerebral hemorrhage, cerebral infarction, or central nervous system disease or mental illness within 6 months, could not cooperate with the completion of therapy and pre-rehabilitation exercise;
  4. Patients have severe infections (such as MODS, etc.) or have allergic reactions to chemotherapy drugs and metabolic disorders;
  5. Concurrent tumors or other diseases requiring simultaneous surgery (except laparoscopic gallbladder surgery);
  6. Emergency surgery is required due to tumor complications (e.g., bleeding, perforation, obstruction);
  7. Patients participating in other clinical trials.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Multimodal prehabilitation group

    Patients received multimodal prehabilitation combined with ERAS before the gastrectomy.

    Behavioral: Multimodal prehabilitation program

  • Active comparator
    ERAS group

    The ERAS pathway was followed in patients in the ERAS group.

    Behavioral: ERAS program

Interventions

  • BehavioralMultimodal prehabilitation program

    Patients adopted planned, structural, repetitive and purposeful approach that includes elements of exercise, nutritional and psychological.Patients were evaluated for changes during neoadjuvant therapy and postoperative recovery

  • BehavioralERAS program

    The core content is to adopt a series of optimized measures performed during the perioperative period on the basis of evidence-based medical findings to reduce the physiological and psychological stress of patients and to accelerate their recovery.

06

What researchers measure

Primary outcomes

  1. Cardiopulmonary capacity

    The 6-minute walk test (6MWT) can be used to measure exercise capacity to reflect cardiopulmonary function.

    Time frame: Baseline (T0), Post-neoadjuvant chemotherapy (through completetion of neoadjuvant therapy, an average of 16 weeks), and prior to surgery(T2)

Secondary outcomes

  1. Patient's quality of life

    QoL comprises patient-reported outcomes (PRO) of physical symptoms and psychosocial health status. Quality of Life Questionnaire (QLQ) C30 is sensitive tool for measuring individual performance status. Each index score ranges from 1 to 4, with higher scores indicating higher risk.

    Time frame: Baseline (T0), Post-neoadjuvant chemotherapy (through completetion of neoadjuvant therapy, an average of 16 weeks), and prior to surgery(T2)

  2. Serum albumin levels

    The level of Serum albumin is used to assess nurtritional status.

    Time frame: Baseline (T0), Post-neoadjuvant chemotherapy (through completetion of neoadjuvant therapy, an average of 16 weeks), and prior to surgery(T2)

  3. sarcopenia

    At the L3 level, total SM will be measured. Skeletal muscle index (SMI) will be calculated as follows: SM/height(m)2. SMI is used to assess nurtritional status.

    Time frame: Baseline (T0), Post-neoadjuvant chemotherapy (through completetion of neoadjuvant therapy, an average of 16 weeks), and prior to surgery(T2)

  4. completetion of neoadjuvant chemotherapy

    Discontinued due to adverse reactions

    Time frame: Post-neoadjuvant chemotherapy (through completetion of neoadjuvant therapy, an average of 16 weeks)

  5. First exhaust and defecation

    First exhaust and defecation is used to assess the postoperative recovery course.

    Time frame: Postoperative (≤30 days after surgery)

  6. First liquid diet

    First liquid diet is used to assess the postoperative recovery course.

    Time frame: Postoperative (≤30 days after surgery)

  7. The incidence of postoperative complications

    Refers to the incidence of early postoperative complications.

    Time frame: Postoperative (≤30 days after surgery)

  8. Duration of postoperative hospital stay

    Duration of postoperative hospital stay in days is used to assess the postoperative recovery course.

    Time frame: Postoperative (≤30 days after surgery)

  9. Hospitalization costs

    The expense from admission to discharge

    Time frame: Postoperative (≤30 days after surgery)

  10. 3-year recurrence-free survival

    3-year recurrence-free survival (RFS) rate

    Time frame: 3 years

  11. 3-year overall survival

    3-year overall survival (OS) rate

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Jan 2025, 7 months after the start.

Of 358 non-industry interventional studies with no phase under Stomach Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 63. This study's planned 7 months is below that.

Counting every sponsor, half of 369 studies reached it within 36 months; a quarter within 17 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2024
First posted
Jul 26, 2024
StartActual
Jun 1, 2024
Primary completionEst.
Jan 1, 2025
CompletionEst.
May 1, 2025
Last update
Jul 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06521541
Responsible party
Sponsor
First posted
Jul 26, 2024
Start date
Jun 1, 2024
Primary completion
Jan 1, 2025 (estimated)
Completion
May 1, 2025 (estimated)
Last update
Jul 26, 2024

Study contacts

Yanbing Zhou, MD
Contact
zhouyanbing@qduhospital.cn
86532-82911324
Qi Liu
Contact
lq112867@163.com
86532-82911324
Yanbing Zhou
study director · The Affiliated Hospital of Qingdao University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion